5-amino-1-(5-N-benzylamino-2,3,-di-O-pivaloyl-5-deoxy-β-D-ribofuranosyl)imidazole-4-carboxamide hydrochloride | 911204-99-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-amino-1-(5-N-benzylamino-2,3,-di-O-pivaloyl-5-deoxy-β-D-ribofuranosyl)imidazole-4-carboxamide hydrochloride
• 英文别名: 5-amino-1-(5-N-benzylamino-2,3,-di-O-pivaloyl-5-deoxy-β-D-ribofuranosyl)imidazole-4-carboxamide；[(2R,3R,4R,5R)-5-(5-amino-4-carbamoylimidazol-1-yl)-2-[(benzylamino)methyl]-4-(2,2-dimethylpropanoyloxy)oxolan-3-yl] 2,2-dimethylpropanoate
• CAS: 911204-99-4
• 化学式: C₂₆H₃₇N₅O₆
• 分子量: 515.61
• InChiKey: CDPWCPNRJKLSPI-WGQQHEPDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  37
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  161
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  5-amino-1-(5-N-benzylamino-2,3,-di-O-pivaloyl-5-deoxy-β-D-ribofuranosyl)imidazole-4-carboxamide hydrochloride 在 盐酸 作用下， 以 甲醇 、 水 为溶剂， 生成 5-amino-1-(5-N-benzylamino-2,3,-di-O-pivaloyl-5-deoxy-β-D-ribofuranosyl)imidazole-4-carboxamide hydrochloride
  参考文献：
  名称：

  WO2006/105167

  摘要：

  公开号：
• 作为产物：
  描述：

  5-amino-1-(5-N-benzylamino-N-benzyloxycarbonyl-2,3-di-O-pivaloyl-5-deoxy-β-D-ribofuranosyl)imidazole-4-carboxamide 在 palladium hydroxide on carbon 氢气 、 溶剂黄146 作用下， 以 乙酸乙酯 为溶剂， 生成 5-amino-1-(5-N-benzylamino-2,3,-di-O-pivaloyl-5-deoxy-β-D-ribofuranosyl)imidazole-4-carboxamide hydrochloride
  参考文献：
  名称：

  WO2006/105167

  摘要：

  公开号：

文献信息

• METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT
  申请人：Stover Richard R.

  公开号：US20080175891A1

  公开（公告）日：2008-07-24

  The present invention provides transdermal administration of AICA riboside, or a prodrugs, analogs, or salts thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.

  本发明提供了通过经皮途径给予AICA核糖苷，或其前药、类似物或盐，和/或血液凝块抑制剂以预防或减少患者的不良副作用。可能受益的患者类型包括左心室功能减退的患者、先前发生心肌梗死的患者、接受非血管手术的患者，或分娩期间的胎儿。
• Methods, Compositions, and Formulations for Preventing or Reducing Adverse Effects in a Patient
  申请人：Mangano T. Dennis

  公开号：US20060293273A1

  公开（公告）日：2006-12-28

  The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.

  本发明提供了与阿卡德西酮、其前药、类似物或盐有关的方法、组合物、配方和试剂盒，以及/或用于预防或减少患者不良副作用的血凝抑制剂。可能受益的患者类型包括左心室功能下降的患者、先前发生心肌梗死的患者、接受非血管手术的患者或分娩期间的胎儿。
• Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
  申请人：Pericor Therapeutics, Inc.

  公开号：EP2594273A1

  公开（公告）日：2013-05-22

  The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.

  本发明提供了与阿卡替辛或其原药、类似物或盐和/或凝血抑制剂有关的方法、组合物、制剂和试剂盒，用于预防或减少患者的不良副作用。可能受益的患者类型包括左心室功能减退的患者、既往患有心肌梗塞的患者、接受非血管手术的患者或分娩期间的胎儿。
• Methods and Compositions for Treatment of Acute Heart Failure
  申请人：Stover Richard R.

  公开号：US20100087500A1

  公开（公告）日：2010-04-08

  The present disclosure provides methods and compositions for treating acute heart failure, by administering to a subject in need thereof a therapeutically effective amount of an AICA riboside analog or a pharmaceutically acceptable salt or prodrug thereof.
• US5777100A
  申请人：——

  公开号：US5777100A

  公开（公告）日：1998-07-07